Key Takeaways
- HSBC shifted Eli Lilly (LLY) rating from Hold to Reduce, lowering price target from $1,070 down to $850
- Analyst Rajesh Kumar believes LLY trades at “priced to perfection” levels following a 20% rally in the last year
- HSBC reduced obesity medication market size projection to $80–120bn by 2032, significantly below Wall Street’s $150bn+ consensus
- Questions emerge around orforglipron revenue expectations, competitive pricing dynamics, and dependence on direct-pay consumers
- LLY shares declined 1.6% to $972.51 post-downgrade; competitor Novo Nordisk (NVO) has plummeted 52% during the same timeframe
Eli Lilly’s performance has been impressive. With shares climbing 20% over twelve months while competitor Novo Nordisk shed over half its market value, LLY appeared to dominate the obesity treatment landscape. However, HSBC believes investor enthusiasm may have outpaced reality.
HSBC analyst Rajesh Kumar issued a Reduce rating on Tuesday, downgrading from Hold and slashing his price objective to $850 from $1,070. Shares retreated 1.6% to $972.51 following the announcement.
Kumar’s thesis centers on a straightforward premise: the stock trades at “priced to perfection” levels, offering minimal margin for disappointment.
Three primary factors drive the downgrade. First is the actual scale of the obesity pharmaceutical market. HSBC now projects a total addressable market reaching $80–120 billion by 2032. This figure sits substantially beneath the $150 billion-plus projections commonly cited across Wall Street.
This discrepancy carries significance. A compressed market opportunity ceiling constrains the revenue expansion already embedded in Lilly’s current valuation.
Orforglipron Sales Forecasts Appear Aggressive
The second worry centers on Lilly’s forthcoming oral obesity treatment, orforglipron. The medication is slated for release later this year and has sparked considerable interest — Street consensus anticipates 2026 revenues between $1.1 billion and $1.3 billion.
HSBC questions these projections. Kumar stated that “the compliance and persistence of these drugs might disappoint,” and observed that estimates seem tied to a $1.5 billion inventory stockpile Lilly has already accumulated in preparation for launch.
Inventory buildup signals management conviction. Yet it simultaneously elevates risk if commercial performance falls short.
Competitive Pricing Dynamics Intensifying
The third issue involves pricing strategy. Lilly confronts anticipated price reductions in 2026 stemming from heightened competitive pressures, with HSBC highlighting “rising working capital intensity” and weakening “rebate dynamics” as cautionary signals.
Kumar additionally noted the divergence between Lilly’s and Novo Nordisk’s forward guidance — a discrepancy that has left most investors puzzled. His interpretation suggests Lilly’s superior results stem from the cash-pay segment, where patients purchase medications directly without insurance coverage.
This distribution channel demonstrates greater sensitivity to macroeconomic fluctuations and, HSBC cautioned, faces potential disruption from AI-driven labour market transformations.
HSBC maintains a constructive view on the broader healthcare sector for the upcoming quarter. Within that framework, however, Kumar characterizes Lilly’s risk-reward profile as unattractive at present valuations.
LLY traded at $972.51 when the downgrade was issued, representing more than $120 above HSBC’s revised $850 price target.
